Research

Area 2

Atherosclerosis, coronary disease and heart failure

Team leader

Strategic objectives

  • To identify the pathophysiological mechanisms involved in the process of accelerated atherosclerosis.
  • To evaluate the clinical efficacy of regenerative cell therapy and carry out further in-depth study of the regulatory mechanisms of the exogenous and endogenous stem cells in ischaemic heart disease and heart failure.
  • To gain an increased understanding of the genetics, pathophysiology, diagnosis and treatment of heart failure.
  • To gain an increased understanding of the organisational models for the care of cardiovascular patients in the community.
  • To gain a more in-depth understanding of the pathophysiology, diagnostic methods and results of new treatments for acute and chronic ischaemic heart disease.
  • To evaluate the repercussions of the new diagnostic techniques and types of treatment in structural heart disease.
  • To study the applicability of the invasive and non-invasive imaging techniques in ischaemic heart disease, heart failure, structural heart disease and cell therapy

Main lines of research

  • Study of the mechanisms of hyperplasia of the intima following coronary revascularisation procedures experimental models.
  • Study of the biocompatibility of the materials and the endothelialisation process in the design of intracoronary devices.
  • Study of the influence of hormonal factors and aging on the regulation of the nitric oxide and superoxide systems in the healthy and population with cardiovascular disease.
  • Determination of the mechanisms involved in the regulation of the nitric oxide and superoxide systems.
  • Study of hypothermia in patients with cardiac arrest.
  • Study of the efficacy of cell therapy in patients with chronic refractory angina pectoris.
  • Analysis of the regulatory mechanisms and the efficacy of the administration of mesenchymal stem cells on myocardial regeneration in an experimental model.
  • Role of the mechanisms of vascular inflammation and thrombosis (circulating endothelial and the progenitor endothelial cells).
  • Study of the impact of gender differences on ischaemic heart disease.
  • Clinical studies evaluating the efficacy and safety of drug-eluting stents coated with everolimus in patients with STsegment elevation myocardial infarction.
  • Clinical evaluation of the fully bioresorbable coronary device in ischaemic heart disease.
  • Chronic total occlusion of coronary arteries in humans: from the pathophysiology to the clinical implications of successful recanalisation.
  • Study of neurohormonal activation and the fibrotic process associated with ventricular remodelling in dilated cardiomyopathy.
  • Genetic study of familial idiopathic cardiomyopathy.
  • Prevention of ventricular dysfunction in chemotherapy patients.
  • Study of heart failure with normal ejection fraction.
  • Evaluation of efficacy of mechanical circulatory support devices.
  • Integration of care models between cardiology and primary care in patients with chronic heart disease.
  • Outpatient characterisation of newonset heart failure using high-resolution imaging.
  • Study of the efficacy and efficiency, of surgical and transcatheter treatment of aortic valve disease.
  • Percutaneous closure of the left atrial appendage in patients with non-valvular atrial fibrillation requiring anticoagulant treatment.
  • Evaluation of the impact of the use of MitraClip in patients with mitral regurgitation.
  • Role of cardiac imaging in the indications, diagnosis, treatment and follow-up of patients with structural heart disease.
  • Utility of the new imaging techniques and biomarkers for the early diagnosis of cardiac involvement in Chagas disease and response to antiparasitic treatment.
  • Utility of cardiac magnetic resonance imaging in pulmonary hypertension and in the detection of right ventricular dysfunction. Evaluation of new pharmacological and invasive treatments for pulmonary hypertension.